-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] For a long time, there have been rebates in the pharmaceutical industry, hindering the healthy development of the industry
.
With the advancement of centralized procurement and stricter industry supervision, representatives of traditional medicine are facing enormous pressure to survive
.
On the one hand, from the perspective of the overall industry environment, with the normalization of centralized procurement, the net profit of many pharmaceutical companies has declined.
In order to control costs, not only domestic companies, but also a large number of pharmaceutical companies including multinational pharmaceutical companies.
The decision to lay off the sales force made life difficult for the medical rep
.
On the other hand, industry supervision has become more stringent, and medical representatives under high policy pressure are further restricted
.
On January 10, the Jiangxi Provincial Health and Health Commission issued the "Notice on Printing and Distributing the Management Measures for Visiting Staff in Medical Representatives' Medical Institutions (2021)"
.
The notice requires that medical representatives who carry out academic and commercial promotion activities of related products in medical institutions should first register and file, and report to the medical ethics and medical ethics department for unified management
.
At the same time, it is clearly stated that if the medical representative violates the relevant regulations, the company's application shall be included in the bad record of commercial bribery in the field of pharmaceutical purchase and sales in Jiangxi Province.
, and will not purchase the company's medicines, medical equipment and medical consumables within two years
.
It is understood that since 2022, a large number of medical representatives have been exposed for violations
.
Including: two medical device industry practitioners in Hubei Province were indicted on suspicion of bribery and bid rigging; two medical representatives of a pharmaceutical company in Beijing and a company in Zhangshu in Jiangxi were arrested and prosecuted on suspicion of bribery; a medical device Co.
, Ltd.
in Taizhou sales The representative was prosecuted for the crime of offering bribes; the former head of the Chinese pharmacy of the Pharmacy Department of a health center in Taizhou Pharmaceutical High-tech Zone was also prosecuted for the crime of offering bribes
.
Pharmaceutical representative industry compliance is imperative
.
So, is there still room for medical representatives in the future? How can we solve the current pain points and difficulties and not be eliminated from the game? The analysis believes that with the advancement of the centralized procurement policy, both pharmaceutical representatives and pharmaceutical companies are facing transformation and upgrading, and pharmaceutical agents need to return to the work standard of pharmaceutical representatives, carry out drug information transmission, communication, and feedback, and pay attention to the academic promotion of drugs
.
In addition, in recent years, new technologies such as artificial intelligence have gradually emerged and have begun to be applied to various fields such as the pharmaceutical industry.
At present, foreign pharmaceutical companies such as Merck & Co.
, as well as local pharmaceutical companies such as Xi'an Janssen, Mingde Bio, and Harbin Pharmaceutical Group have all involved artificial intelligence.
, transforming by actively embracing digital
.
The industry believes that artificial intelligence will help pharmaceutical companies to transform and develop digitally, compliantly, and intelligently.
With the deepening of cooperation between pharmaceutical companies and artificial intelligence, virtual medical representatives will also emerge in the future, which can actively respond to the needs of all parties, such as The needs of pharmaceutical representatives for compliant interaction, wide customer coverage, high efficiency, and more professional communication, the needs of doctors to obtain medication consultation and assistance anytime, anywhere, and the needs of pharmaceutical companies for innovative marketing in response to policy changes and market challenges
.
Compared with the academic promotion method of traditional pharmaceutical generation, virtual pharmaceutical generation breaks through geographical restrictions and has a wider coverage, which can also improve efficiency and reduce costs
.
It is worth mentioning that whether it is a traditional offline pharmaceutical agent or a virtual pharmaceutical agent, pharmaceutical companies need to follow the concept of safe and compliant operation to provide customers with better services
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
With the advancement of centralized procurement and stricter industry supervision, representatives of traditional medicine are facing enormous pressure to survive
.
On the one hand, from the perspective of the overall industry environment, with the normalization of centralized procurement, the net profit of many pharmaceutical companies has declined.
In order to control costs, not only domestic companies, but also a large number of pharmaceutical companies including multinational pharmaceutical companies.
The decision to lay off the sales force made life difficult for the medical rep
.
On the other hand, industry supervision has become more stringent, and medical representatives under high policy pressure are further restricted
.
On January 10, the Jiangxi Provincial Health and Health Commission issued the "Notice on Printing and Distributing the Management Measures for Visiting Staff in Medical Representatives' Medical Institutions (2021)"
.
The notice requires that medical representatives who carry out academic and commercial promotion activities of related products in medical institutions should first register and file, and report to the medical ethics and medical ethics department for unified management
.
At the same time, it is clearly stated that if the medical representative violates the relevant regulations, the company's application shall be included in the bad record of commercial bribery in the field of pharmaceutical purchase and sales in Jiangxi Province.
, and will not purchase the company's medicines, medical equipment and medical consumables within two years
.
It is understood that since 2022, a large number of medical representatives have been exposed for violations
.
Including: two medical device industry practitioners in Hubei Province were indicted on suspicion of bribery and bid rigging; two medical representatives of a pharmaceutical company in Beijing and a company in Zhangshu in Jiangxi were arrested and prosecuted on suspicion of bribery; a medical device Co.
, Ltd.
in Taizhou sales The representative was prosecuted for the crime of offering bribes; the former head of the Chinese pharmacy of the Pharmacy Department of a health center in Taizhou Pharmaceutical High-tech Zone was also prosecuted for the crime of offering bribes
.
Pharmaceutical representative industry compliance is imperative
.
So, is there still room for medical representatives in the future? How can we solve the current pain points and difficulties and not be eliminated from the game? The analysis believes that with the advancement of the centralized procurement policy, both pharmaceutical representatives and pharmaceutical companies are facing transformation and upgrading, and pharmaceutical agents need to return to the work standard of pharmaceutical representatives, carry out drug information transmission, communication, and feedback, and pay attention to the academic promotion of drugs
.
In addition, in recent years, new technologies such as artificial intelligence have gradually emerged and have begun to be applied to various fields such as the pharmaceutical industry.
At present, foreign pharmaceutical companies such as Merck & Co.
, as well as local pharmaceutical companies such as Xi'an Janssen, Mingde Bio, and Harbin Pharmaceutical Group have all involved artificial intelligence.
, transforming by actively embracing digital
.
The industry believes that artificial intelligence will help pharmaceutical companies to transform and develop digitally, compliantly, and intelligently.
With the deepening of cooperation between pharmaceutical companies and artificial intelligence, virtual medical representatives will also emerge in the future, which can actively respond to the needs of all parties, such as The needs of pharmaceutical representatives for compliant interaction, wide customer coverage, high efficiency, and more professional communication, the needs of doctors to obtain medication consultation and assistance anytime, anywhere, and the needs of pharmaceutical companies for innovative marketing in response to policy changes and market challenges
.
Compared with the academic promotion method of traditional pharmaceutical generation, virtual pharmaceutical generation breaks through geographical restrictions and has a wider coverage, which can also improve efficiency and reduce costs
.
It is worth mentioning that whether it is a traditional offline pharmaceutical agent or a virtual pharmaceutical agent, pharmaceutical companies need to follow the concept of safe and compliant operation to provide customers with better services
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
